UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 72

Sortiert nach

Abstract C261: Pharmacokinetics (PK) and pharmacodynamics (PD) of the oral transforming growth factor-beta (TGF-β) receptor I kinase inhibitor LY2157299 monohydrate (LY) in hepatocellular carcinoma (HCC) compared to glioma patients

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.C261-C261

2013

Link zum Volltext

Verfügbarkeit prüfen

ACTR-16. PHASE 2 STUDY EVALUATING SAFETY, PHARMACOKINETICS (PK), PHARMACODYNAMICS (PD) AND EFFICACY OF THE ORAL TRANSFORMING GROWTH FACTOR-BETA (TGF-β) RECEPTOR I KINASE INHIBITOR GALUNISERTIB WHEN COMBINED WITH CHEMORADIOTHERAPY IN NEWLY DIAGNOSED MALIGNANT GLIOMA

Neuro-oncology (Charlottesville, Va.), 2016-11, Vol.18 (suppl_6), p.vi4-vi4

2016

Link zum Volltext

Verfügbarkeit prüfen

Amyloid re‐accumulation after donanemab treatment: summary from 3 interventional trials

Alzheimer's & dementia, 2023-12, Vol.19 (S14), p.n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Assessment of In Vivo Clinical Product Performance of a Weak Basic Drug by Integration of In Vitro Dissolution Tests and Physiologically Based Absorption Modeling

The AAPS journal, 2015-11, Vol.17 (6), p.1395-1406

2015

Link zum Volltext

Verfügbarkeit prüfen

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine

International journal of molecular sciences, 2017-05, Vol.18 (5), p.995

2017

Link zum Volltext

Verfügbarkeit prüfen

Cardiac Safety of TGF-[beta] Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study

Cardiovascular toxicology, 2015-10, Vol.15 (4), p.309

2015

Link zum Volltext

Verfügbarkeit prüfen

Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study

Cardiovascular toxicology, 2015-10, Vol.15 (4), p.309-323

2015

Link zum Volltext

Verfügbarkeit prüfen

Case Series of Cancer Patients Treated With Galunisertib, a Transforming Growth Factor-Beta Receptor I Kinase Inhibitor in a First-in-Human Dose Study

Journal of medical cases, 2014, Vol.5 (11), p.603-609

2014

Link zum Volltext

Verfügbarkeit prüfen

Chimerism and tolerance post-in utero transplantation with embryonic stem cells

Transplantation, 2004-11, Vol.78 (9), p.1274

2004

Link zum Volltext

Verfügbarkeit prüfen

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

Drug design, development and therapy, 2015-01, Vol.9 (default), p.4479-4499

2015

Link zum Volltext

Verfügbarkeit prüfen

A comment on the "correction" of tissue-plasma partition coefficients for drug extraction in eliminating organs by Sven Björkman

Journal of pharmacokinetics and pharmacodynamics, 2005-12, Vol.32 (5-6), p.659-662

2005

Link zum Volltext

Verfügbarkeit prüfen

Defining a therapeutic window for the novel TGF‐β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

British journal of clinical pharmacology, 2014-05, Vol.77 (5), p.796-807

2014

Link zum Volltext

Verfügbarkeit prüfen

Defining a therapeutic window for the novel TGF ‐β inhibitor LY 2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

British journal of clinical pharmacology, 2014-05, Vol.77 (5), p.796-807

2014

Link zum Volltext

Verfügbarkeit prüfen

Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug–drug interaction trials

British journal of clinical pharmacology, 2010-10, Vol.70 (4), p.523-536

2010

Link zum Volltext

Verfügbarkeit prüfen

Development of a whole body physiologically based model to characterise the pharmacokinetics of benzodiazepines. 1: Estimation of rat tissue-plasma partition ratios

Journal of pharmacokinetics and pharmacodynamics, 2004-08, Vol.31 (4), p.269-298

2004

Link zum Volltext

Verfügbarkeit prüfen

Diazepam pharamacokinetics from preclinical to phase I using a bayesian population physiologically based pharmacokinetic model with informative prior distributions in winbugs

Journal of pharmacokinetics and pharmacodynamics, 2006-10, Vol.33 (5), p.571-594

2006

Link zum Volltext

Verfügbarkeit prüfen

Disease progression model using the integrated Alzheimer's Disease Rating Scale

Alzheimer's & dementia, 2023-06, Vol.19 (6), p.2253-2264

2023

Link zum Volltext

Verfügbarkeit prüfen

Disposition and metabolism of [14C]-galunisertib, a TGF-βRI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics

Xenobiotica, 2018-04, Vol.48 (4), p.382-399

2018

Link zum Volltext

Verfügbarkeit prüfen

Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease

Alzheimer's & dementia : translational research & clinical interventions, 2023-04, Vol.9 (2), p.e12404-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Donanemab exposure‐efficacy relationship in patients with early symptomatic Alzheimer’s disease

Alzheimer's & dementia, 2023-06, Vol.19 (S7), p.n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease

Clinical pharmacology and therapeutics, 2023-06, Vol.113 (6), p.1258-1267

2023

Link zum Volltext

Verfügbarkeit prüfen

Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer

European journal of cancer (1990), 2016-10, Vol.66, p.95-103

2016

Link zum Volltext

Verfügbarkeit prüfen

Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin

Journal of pharmacokinetics and pharmacodynamics, 2010-02, Vol.37 (1), p.3-24

2010

Link zum Volltext

Verfügbarkeit prüfen

First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma

Clinical cancer research, 2015-02, Vol.21 (3), p.553-560

2015

Link zum Volltext

Verfügbarkeit prüfen

Fuzzy simulation of pharmacokinetic models: Case study of whole body physiologically based model of diazepam

Journal of pharmacokinetics and pharmacodynamics, 2004-06, Vol.31 (3), p.185-213

2004

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 72

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieCancer Research

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(70)
Mit Volltextzugriff
(67)

Publikationsform

Artikel
(71)
Dissertationen
(1)

Sprache

Englisch
(72)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Abstract C261: Pharmacokinetics (PK) and pharmacodynamics (PD) of the oral transforming growth factor-beta (TGF-β) receptor I kinase inhibitor LY2157299 monohydrate (LY) in hepatocellular carcinoma (HCC) compared to glioma patients

ACTR-16. PHASE 2 STUDY EVALUATING SAFETY, PHARMACOKINETICS (PK), PHARMACODYNAMICS (PD) AND EFFICACY OF THE ORAL TRANSFORMING GROWTH FACTOR-BETA (TGF-β) RECEPTOR I KINASE INHIBITOR GALUNISERTIB WHEN COMBINED WITH CHEMORADIOTHERAPY IN NEWLY DIAGNOSED MALIGNANT GLIOMA

Amyloid re‐accumulation after donanemab treatment: summary from 3 interventional trials

Assessment of In Vivo Clinical Product Performance of a Weak Basic Drug by Integration of In Vitro Dissolution Tests and Physiologically Based Absorption Modeling

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine

Cardiac Safety of TGF-[beta] Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study

Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study

Case Series of Cancer Patients Treated With Galunisertib, a Transforming Growth Factor-Beta Receptor I Kinase Inhibitor in a First-in-Human Dose Study

Chimerism and tolerance post-in utero transplantation with embryonic stem cells

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

A comment on the "correction" of tissue-plasma partition coefficients for drug extraction in eliminating organs by Sven Björkman

Defining a therapeutic window for the novel TGF‐β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

Defining a therapeutic window for the novel TGF ‐β inhibitor LY 2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug–drug interaction trials

Development of a whole body physiologically based model to characterise the pharmacokinetics of benzodiazepines. 1: Estimation of rat tissue-plasma partition ratios

Diazepam pharamacokinetics from preclinical to phase I using a bayesian population physiologically based pharmacokinetic model with informative prior distributions in winbugs

Disease progression model using the integrated Alzheimer's Disease Rating Scale

Disposition and metabolism of [14C]-galunisertib, a TGF-βRI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics

Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease

Donanemab exposure‐efficacy relationship in patients with early symptomatic Alzheimer’s disease

Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease

Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer

Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin

First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma

Fuzzy simulation of pharmacokinetic models: Case study of whole body physiologically based model of diazepam

Aktive Filter

Suchergebnisse filtern